Mark Gluzman

Dr. Mark Gluzman

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2017 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MGMark Gluzman
Mark Gluzman
VKVictor Kashchenko
Victor Kashchenko
AKAleksei Mikhailovich Karachun
Aleksei Mikhailovich Karachun
RORashida Vakhidovna Orlova
Rashida Vakhidovna Orlova
INIakov Aleksandrovich Nakatis
Iakov Aleksandrovich Nakatis
AKAnton Sergeevich Klimov
Anton Sergeevich Klimov
Background: Gastrointestinal stromal tumors (GIST) comprise about 80% of gastrointestinal sarcomas. In patients with localized disease, surgery is considered as “Gold Standard” treatment. Organ-sparing radical en-block resection is widely accepted practice. Since lymph node dissection is not routinely indicated, minimally invasive approach is of particular interest. The aim of this study is to investigate the short-term outcomes of different surgical treatment of GISTs. Methods: We analyzed data of 116 patients who received surgical treatment for localized forms of GIST. Tumors were located in the stomach in 87 (75%) cases, in the small intestine in 26 (22.4%) cases, and extragastrointestinal GISTs were found in 3 (2.6%) patients. Four different approaches were used—open surgery (OpS, n=48), laparoscopic surgery (LS, n=40), endoscopic procedures (EP, n=22) and hybrid rendezvous (HR, n=6). Patient demographics, clinical presentation of tumors, characteristics of operation procedures (duration, intraoperative blood loss, frequency of R0-resection and fragmentation of tumor), postoperative complications and length of hospital stay were examined in all these groups. Results: Radical treatment (R0-resection) was performed in all patients. There were no cases of tumor ruptures during surgical procedure. Mean size of GIST in OpS was 9.1±2.0 [2–35] cm; in LS: 4.9±0.8 (1.5–15) cm; in HR: 3.5±0.8 (2–4.5) cm and in EP: 2.3±0.3 (0.4–3.5) cm. Intraoperative blood loss in OpS was 369.7±209.5 [0–4,000] mL; LS: 63.9±16.0 [0–150] mL; in HR: 96.7±44.3 [50–200] mL; in EP: 33.3±11.0 [0–150] mL. Duration of operation in OpS was 160±20.4 [50–310] min; in LS: 104.7±12.7 [50–185]; in HR: 176.7±44.0 [110–260] min and in EP: 89.8±15.5 [25–190] min. Complication rate in OpS was 5 (10.4%); in LS: 3 (7.5%); in HR: 0% and in EP: 3 (13.6%). Length of hospital stay in OpS was 13.8±2.2 [7–52] days; in LS: 11, 4±2.2 [4–21] days; in HR: 11±3.2 [7–15] days and in EP: 11, 9±2.1 [5–22] days. There were no postoperative deaths. Conclusions: There is a diversity of surgical approaches for GISTs treatment. From our point of view, the main selection criteria for certain procedure are size, localization, growth type of the tumor and status of overlying mucosa. Nevertheless, due to relative rarity and heterogeneity of this pathology, individualization is necessary in each specific case. Laparoscopic and endoscopic surgery is proved to be safe and feasible for resection of the gastric GISTs, with a reasonable operation time, low blood loss, and an acceptable complication rate. Immediate results indicate that all interventions were performed radically without mortality or serious morbidity.

30 April 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
TSTatyana N. Sokolova
Tatyana N. Sokolova
TSTatyana I. Solov'EVa
Tatyana I. Solov'EVa
SASvetlana Aleksakhina
Svetlana Aleksakhina
MBMarina B. Bolieva
Marina B. Bolieva
VGViktor E. Goldberg
Viktor E. Goldberg
ШАШвайко Ксения Анатольевна
Швайко Ксения Анатольевна
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA alterations are actionable, as such neoplasms can be treated with a combination of fulvestrant and the PI3K inhibitor alpelisib. As PIK3CA mutations have an extremely versatile effect on the characteristics of a tumor cell, numerous associations of PIK3CA mutations and various clinico-pathological characteristics of BC can be traced. Aim. Our aim was to clarify the information on the frequency and spectrum of PIK3CA mutations in Russian patients with HR+/HER2- advanced BC, and to study the association of PIK3CA mutations with clinical and pathological parameters of BC. Materials and methods. Tissue samples from 694 patients with HR+/HER2- advanced BC (mixed population of primary metastatic and relapsed tumors) who received any line of anti-cancer treatment in Dec 2020 to June 2021 in Russian Federation were analyzed by high-resolution melting, allele-specific PCR, digital droplet PCR and Sanger sequencing (exons 7,9, and 20 of the PIK3CA gene). Mutation rates in different BC subgroups were compared using the Fishers exact test. The age at diagnosis in patients with different PIK3CA status was compared using the MannWhitney U-test. The relationship between the PIK3CA status and the degree of tumor differentiation was compared using the CochraneArmitage test for trends. Luminal A and B BC expression subtypes were distinguished with surrogate IHC markers according to St.-Gallen recommendations (2013). Results. Mutations were identified in 220/694 (32%) BC patients. The three most frequent missense substitutions in the PIK3CA gene (p.E542K, p.E545K, and p.H1047R) accounted for 190/220 (86%) mutations. Associations of PIK3CA mutations with luminal A subtype of BC, low proliferation index, small size of the primary tumor, and absence of signs of hereditary cancer were revealed. Associations of mutations in the kinase domain of PIK3CA (p.H1047R) with late recurrence of locally advanced BC and with non-Slavic ethnic origin of patients were found. Conclusion. PIK3CA mutation rate of 32% confirms high prevalence of mutation in Russian population, with some differences reflecting the ethnic origin of patients.

27 June 2019 in Malignant tumours
Verified
Journal Article
Open access
PDF file
ROR. V. Orlova
R. V. Orlova
NTN. V. Tyukavina
N. V. Tyukavina
MGMark Gluzman
Mark Gluzman
APA. E. Protasova
A. E. Protasova
GRG. A. Raskin
G. A. Raskin
АKА. D. Khalikov
А. D. Khalikov
Случай использования ингибитора контрольных точек у больной раком шейки матки в реальной клинической практике

1 April 2025 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
ASAleksandr Sultanbaev
Aleksandr Sultanbaev
DDDaria Dubovichenko
Daria Dubovichenko
MMMakhabbat Murzalina
Makhabbat Murzalina
AVAlexander Volkov
Alexander Volkov
MGMark Gluzman
Mark Gluzman
The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population. This multicenter retrospective cohort study assessed the real-world efficacy and safety of Len + Pembro in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53% of patients, and 90% had metastases to ≥ 2 organs. ORR was 48.33%, disease control rate was 86.7%, and median PFS was 19.0 months. Grade ≥ 3 adverse events occurred in 25% of patients, with 33.3% requiring lenvatinib dose reductions. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.

30 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TSTatyana N. Sokolova
Tatyana N. Sokolova
GYGrigoriy A. Yanus
Grigoriy A. Yanus
SASvetlana Aleksakhina
Svetlana Aleksakhina
YBYana V. Belysheva
Yana V. Belysheva
ACAleksandra P. Chernyakova
Aleksandra P. Chernyakova
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
Background: Several targeted drugs have been recently approved for the treatment of PIK3CA-mutated hormone receptor-positive (HR+)/HER2-negative (HER2−) breast cancer (BC). This study aimed at a comprehensive evaluation of the spectrum of PIK3CA alterations in Russian BC patients. Methods: The tumor material from 1872 patients with ER+/HER2− BC was tested by a combination of PCR-based methods. Results: Mutations were detected in 693/1872 (37%) cases, including 46 BC with two PIK3CA lesions. The three most common substitutions (E542K, E545K, and H1047R) were identified in 542/693 (78%) PIK3CA-mutated cases, while as many as 5.5–12% of identified mutations were not potentially detectable by common commercial kits. The study included patients of Slavic and non-Slavic ethnicities residing in regions with different climate conditions, however, these factors did not influence the distribution of PIK3CA mutations. The presence of PIK3CA variants was associated with older patient age at diagnosis (p = 0.0002), smaller tumor size (p = 0.005), lower grade (p = 0.005), Ki67 <20% (p = 0.0001) and progesterone receptor-positive status (p = 0.002) at the initial disease diagnosis, and fewer distant metastases at the time of the detection of BC spread (p = 0.0001). In a subgroup of 413 BC patients who received adjuvant tamoxifen or aromatase inhibitors, PIK3CA mutations were not associated with resistance to either type of treatment. Conclusions: The results of this study highlight the need to extend the PIK3CA testing beyond the hotspot regions of this gene. Although PIK3CA alterations contribute to the pathogenesis of HR+/HER2− BC and represent a target for several novel drugs, they are not intrinsically associated with unfavorable clinical characteristics of this subtype of cancer disease.

25 March 2024 in Clinical Case in Oncology
Verified
Journal Article
Open access
PDF file
MGMark Gluzman
Mark Gluzman
NTN. V. Tyukavina
N. V. Tyukavina
DRD. S. Rudenko
D. S. Rudenko
ROR. V. Orlova
R. V. Orlova
Ovarian cancer is a serious problem in clinical oncology due to the frequent detection of the disease in late stages, as well as the extremely low effectiveness of treatment at the stage of development of resistance to platinum drugs. The use of immunotherapy in this setting is not a standard option, but several early phase trials of its potential effectiveness are described in the literature. This clinical case presents a successful experience with the use of immune checkpoint inhibitors in a pretreated patient with platinum-resistant metastatic ovarian cancer, which was accompanied by various immune-related adverse events.